Vivos' cost-cutting initiatives also led to a $1 million or 27% year-over-year reduction in operating loss, versus the third quarter of 2023. For the nine months ended September 30, 2024 operating ...

(“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for ...

Researchers released new clinical guidelines for treating restless legs syndrome (RLS), emphasizing patient-centered care and ...

Mouth tape is often a simple, non-invasive method of promoting nasal breathing, which can result in a more peaceful, restful ...

The randomized trial linked Livanova’s aura6000 to improvements on measures of OSA severity and blood oxygen after six months of treatment with the hypoglossal ... see ways that Livanova could ...

A recent study showed that mouth taping, as mimicked by closing the mouth in people with sleep apnea, may not be the cure-all ...

An unhealthy diet and an indolent life are well known causes of heart disease and stroke. But sleep apnea—where people ...

The primary treatment for people with moderate or severe OSA is a continuous positive ... Tongue trainer: In 2021, the Food ...

Think of the heart as a pump that works tirelessly every day. But sometimes, this pump starts to weaken, which is what ...

A key player in the market, Apnea Sciences Corporation contributes to innovative solutions that address the diverse causes of snoring. Its commitment to research and development positions it as a ...

LivaNova today announced that its OSPREY trial of nerve stimulation for treating sleep apnea met its primary endpoints.